Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Five RNAi-Related Patent Applications: Aug 10, 2006

Premium
Title: Double-Stranded and Single-Stranded RNA Molecules with 5’ Triphosphates and Their Use for Inducing Interferon
 
Number: 20060178334
 
Filed: Feb. 6, 2006
 
Lead Inventor: John Rossi, City of Hope
 
According to the patent application’s abstract, the invention comprises “double-stranded and single-stranded RNA molecules and their use in methods for inducing interferon. … The interferon induction provides anti-viral and other medically useful effects, such as anti-cancer effects. Also provided are methods for reducing or inhibiting interferon induction exhibited by such molecules, particularly siRNA and shRNA molecules produced in vitro.”
 

 
Title: RNAi Probes Targeting Cancer-Related Proteins
 
Number: 20060178329
 
Filed: Feb. 23, 2006
 
Lead Inventor: Martin Gleave, University of British Columbia (OncoGeneX Technologies)
 
The patent application, its abstract states, covers “RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma, and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf.”
The abstract also states that “the invention [further] provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma, and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.”
 

 
Title: Devices, Systems, and Methods for Improving Memory and/or Cognitive Function Through Brain Delivery of siRNA
 
Number: 20060178328
 
Filed: Oct. 19, 2005
 
Inventor: William Kaemmerer, Medtronic
 
The invention, the patent application’s abstract states, “relates to devices, systems, and methods for improving memory and/or cognitive function by brain delivery of compositions of small interfering RNA or vectors containing the DNA encoding for small interfering RNA. Such compositions can be administered using devices, systems, and methods for direct delivery of the compositions to the brain, or using devices, systems, methods of delivery, and compositions that deliver small interfering RNA or vectors containing the DNA encoding the small interfering RNA across the blood-brain barrier. The … invention also provides valuable small interfering RNA vectors, and methods for reduction of BACE1 levels in the hippocampus, cerebral cortex, or other regions of the brain that have beneficial effects on improving memory and/or cognitive function in a subject,” the abstract adds.
 

 
Title: Inhibition of Gene Expression by Delivery of Specially Selected Double-Stranded or Other Forms of Small Interfering RNA Precursors Enabling the Formation and Function of Small Interfering RNA In Vivo and In Vitro
 
Number: 20060178327
 
Filed: May 13, 2004
 
Inventor: Wah Hin Alex Yeung, Plasmagene Limited
“The use of specially selected sequences from the target gene into designing double-stranded or other forms of RNA (siRNA precursors or siRNAp) that enables small interfering RNA from this new invention is delivered for inhibition of cellular gene expression,” the patent application’s abstract states. “Diseases may be prevented and treated by this process, e.g. severe acute respiratory syndrome and human immunodeficiency virus infections. The process may be practiced in vivo or in vitro. The small interfering RNA enabled is of sequences usually of 23 nucleotides or less,” the abstract notes. “The invented method of sequence selection from the target gene, however, may be applicable to double-stranded RNA of any length.”
 

 
Title: Lipophilic Derivatives of Double-Stranded Ribonucleic Acid
 
Number: 20060178324
 
Filed: Jan. 21, 2004 PCT Filed: Jan. 21, 2004
 
Lead Inventor: Philipp Hadwiger, Alnylam Europe
 
The invention “relates to a double-stranded ribonucleic acid having improved efficiency of inhibition of gene expression, methods of making the dsRNA, and pharmaceutical compositions comprising the dsRNA,” the patent application’s abstract states. “The dsRNA comprises an RNA strand (complementary RNA strand) having a region which is complementary to an RNA transcript of at least a part of a target gene, and at least one covalently linked lipophilic group. The dsRNA are useful for inhibiting the expression of a target gene, as well as for treating diseases caused by expression of the target gene,” the abstract adds. “The invention also relates to methods for inhibiting the expression of a target gene, as well as methods for treating diseases caused by the expression of the gene.”

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.